Clinical and molecular epidemiology of methicillin-resistant Staphylococcus aureus in New Zealand: rapid emergence of sequence type 5 (ST5)-SCCmec-IV as the dominant community-associated MRSA clone. by Williamson, D. et al.
Clinical and Molecular Epidemiology of Methicillin-
Resistant Staphylococcus aureus in New Zealand: Rapid
Emergence of Sequence Type 5 (ST5)-SCCmec-IV as the
Dominant Community-Associated MRSA Clone
Deborah A. Williamson1,2,3*, Sally A. Roberts2, Stephen R. Ritchie1, Geoffrey W. Coombs4,5,
John D. Fraser1, Helen Heffernan3
1 Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand, 2Department of Clinical Microbiology, Auckland District Health Board,
Auckland, New Zealand, 3 Institute of Environmental Science and Research, Wellington, New Zealand, 4 PathWest Laboratory Medicine, Perth, Australia, 5Curtin
University, Perth, Australia
Abstract
The predominant community-associated MRSA strains vary between geographic settings, with ST8-IV USA300 being the
commonest clone in North America, and the ST30-IV Southwest Pacific clone established as the dominant clone in New
Zealand for the past two decades. Moreover, distinct epidemiological risk factors have been described for colonisation and/
or infection with CA-MRSA strains, although these associations have not previously been characterized in New Zealand.
Based on data from the annual New Zealand MRSA survey, we sought to describe the clinical and molecular epidemiology
of MRSA in New Zealand. All non-duplicate clinical MRSA isolates from New Zealand diagnostic laboratories collected as part
of the annual MRSA survey were included. Demographic data was collected for all patients, including age, gender, ethnicity,
social deprivation index and hospitalization history. MRSA was isolated from clinical specimens from 3,323 patients during
the 2005 to 2011 annual surveys. There were marked ethnic differences, with MRSA isolation rates significantly higher in
Māori and Pacific Peoples. Over the study period, there was a significant increase in CA-MRSA, and a previously unidentified
PVL-negative ST5-IV spa t002 clone replaced the PVL-positive ST30-IV Southwest Pacific clone as the dominant CA-MRSA
clone. Of particular concern was the finding of several successful and virulent MRSA clones from other geographic settings,
including ST93-IV (Queensland CA-MRSA), ST8-IV (USA300) and ST772-V (Bengal Bay MRSA). Ongoing molecular surveillance
is essential to prevent these MRSA strains becoming endemic in the New Zealand healthcare setting.
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Introduction
The global emergence of community-associated methicillin-
resistant Staphylococcus aureus (CA-MRSA) over the past two decades
has been well described [1]. Of note, the predominant CA-MRSA
vary between geographic settings, with USA300 the overwhelm-
ingly dominant CA-MRSA clone in North America, and the ST93
Queensland CA-MRSA clone emerging as the most common CA-
MRSA clone in Australia [2,3]. In particular, the epidemic spread
of the USA300 clone throughout North America has resulted in
considerable morbidity, with several studies describing increasing
rates of emergency department attendances and hospitalizations
for CA-MRSA-associated skin and soft tissue infections (SSTI)
[4,5].
Initial reports of CA-MRSA strains described the emergence of
these strains in patients with a lack of traditional epidemiological
risk factors for MRSA infection and/or colonization [6]. In
particular, patients with CA-MRSA infections were younger, had
minimal comorbid illness and lacked prior healthcare contact
compared to those patients with infections due to healthcare-
associated MRSA (HCA-MRSA) strains [7,8]. Furthermore,
distinct socio-demographic associations have been described for
CA-MRSA infection, including ethnicity, socioeconomic depriva-
tion and incarceration [1]. Recently however, as the prevalence of
CA-MRSA strains has increased, the epidemiological distinction
between these strains and HCA-MRSA strains has become less
well defined, with numerous reports of nosocomial outbreaks of
infections due to CA-MRSA strains [9,10].
In New Zealand, the ST30 South West Pacific (SWP) clone has
been the predominant CA-MRSA for the past two decades [11].
Similar to prevalent CA-MRSA strains in other settings, ST30
SWP is characterized by carriage of the type IV SCCmec element,
and of the lukF-PV and lukS-PV genes [12]. However, recent
surveillance data suggest that an ST5-SCCmec IV (ST5-IV) CA-
MRSA clone may be emerging as a more common cause of CA-
MRSA infection in New Zealand [13]. To date however, relatively
little is known about the distinct epidemiological associations for
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CA-MRSA infection in New Zealand, although a previous study
suggested that infection with CA-MRSA strains may be more
common in Māori (Indigenous New Zealander) and Pacific Island
populations (Pacific Peoples) [14]. Moreover, the comparative
burden and epidemiology of CA-MRSA and HCA-MRSA
infections has not previously been described in our geographic
setting.
In this context, we sought to (i) describe the clinical and
molecular epidemiology of MRSA in New Zealand, and (ii) to
describe the emergence of a previously unidentified ST5-IV
MRSA strain as the predominant CA-MRSA clone in New
Zealand.
This work was presented, in part, at the 52nd Interscience
Conference on Antimicrobial Agents and Chemotherapy, 2012 in
San Francisco.
Methods
Setting, Patients and Data Collection
New Zealand is an island nation located in the South West
Pacific, with a resident population of approximately 4.4 million.
The population is ethnically diverse, consisting of 67% European,
15% Māori, 10% Asian, 7% Pacific Peoples and 1% of other
ethnicities [15].
In New Zealand, a national survey of MRSA isolates is
performed in August of each year. All New Zealand community
and hospital laboratories refer consecutive, non-duplicate MRSA
isolates to the Institute of Environmental Science and Research
(ESR), Wellington, New Zealand for molecular typing. As part of
this survey, basic patient data is collected, including age, gender
and specimen type (clinical vs. screening isolate). We analyzed
patient data from each year of the survey between 2005 and 2011.
In order to minimize any influence that changes in screening
practices may have had on MRSA isolation rates, demographic
analysis was restricted to those patients who had a clinical isolate
sent for testing. Using hospital admission data recorded by the
New Zealand Ministry of Health, the following additional
demographic information was extracted about each patient:
ethnicity, number of previous hospitalizations in the preceding
year, and socioeconomic status based on the New Zealand
deprivation index (NZDep). The NZDep score is an area-based
measure of deprivation derived from census data, and is based on
the following variables of deprivation: household income, house-
hold ownership, household occupancy, employment and educa-
tion levels, access to independent transportation and access to
telecommunications. It is expressed as a score between one and
ten, a score of ten representing the most deprived neighborhoods
[16]. For analysis, ethnicity was grouped into four major ethnic
groupings: European, Māori, Pacific Peoples and Asian/other
ethnicities. When MRSA isolation was associated with a hospital
attendance or admission, all hospital discharge diagnoses related to
that event were obtained, coded using the International Classification
of Diseases, Tenth Edition, Clinical Modification (ICD-10-CM) codes
[17].
Cases were described as community-associated (CA-MRSA) if
MRSA was isolated from a patient within 48 hours of hospital
admission and/or who: (i) had no history of hospitalization or
surgery in the preceding calendar year (ii) did not reside in
a long-term care facility (LTCF) and (iii) did not have any prior
or current ICD-10-CM discharge diagnoses relating to hemodi-
alysis or implantable devices. Conversely, cases were described
as healthcare-associated (HCA-MRSA) if one or more of these
risk factors were documented. Similar to previously described
methodology [18], we further described healthcare-associated
cases as hospital-onset (HCA-HO) or community-onset (HCA-
CO) depending on whether the specimen was taken .48 hours
or #48 hours, respectively, following hospital admission.
Isolate Collection and Analysis
Identification of S. aureus isolates and determination of
methicillin resistance was carried out by individual laboratories
prior to sending specimens to ESR. Prior to 2009, bacterio-
phage typing was the routine method used to type MRSA at
ESR, as previously described [19]. From 2009 onwards,
molecular typing was performed by PCR amplification and
sequencing of the polymorphic X region of the staphylococcal
protein A (spa) gene, using previously described methods [20].
An internal validation study was conducted in 2009 to ensure
concordance between the two typing methods (data not shown).
spa sequences were analysed using Ridom StaphType software,
Version 2.0.3 (Ridom GmbH, Würzburg, Germany). Clustering
of clonal complexes of related spa types (Spa-CCs) was
performed using the based upon repeat pattern (BURP)
algorithm of the Ridom software [21]. In addition to phage
and spa typing, pulsed-field gel electrophoresis (PFGE) and
multi-locus sequence typing (MLST) were used to further define
and characterize MRSA strains. PFGE and MLST were
performed as previously described [22,23]. SCCmec typing and
PCR amplification for detection of lukF-PV and lukS-PV genes
was performed on representative isolates from each inferred
MLST clonal complex, using previously described methods
[24,25].
Statistics and Rates
Period-prevalence rates of MRSA isolation from clinical
specimens were calculated per 100,000 population, and were
stratified according to age and ethnicity. Population denominator
data were obtained from Statistics New Zealand (http://www.
stats.govt.nz). Categorical variables were compared using either
the x2 or Fisher’s exact test. Non-parametric data were analysed
using the Mann-Whitney U test. Odds ratios were calculated with
95% confidence intervals. A regression model was used to
determine changes in period-prevalence rates over time. A two-
tailed P value of ,0.05 was considered significant, and all
statistical analysis was performed using SPSS software (Version
19).
Ethics
The Multi-Region Ethics Committee, New Zealand granted
ethical approval for this study. As this was an observational study
using de-identified patient information, the Ethics Committee
waived the need for written informed consent.
Results
Patients and Period-prevalence Rates of MRSA Isolations
MRSA was isolated from clinical specimens from 3,323 patients
during the 2005 to 2011 annual surveys. The overall period-
prevalence rate of clinical MRSA isolation increased significantly
from 8.6 to 18.0 per 100,000 population (P,0.001; Figure 1A).
When stratified by age, the highest period-prevalence rates were in
the under five and over 65 year age groups (Figure 1A). Full
demographic information, including ethnicity was available for
2878 patients. When stratified by ethnicity, period-prevalence
rates of MRSA isolations were consistently higher in Māori and
Pacific Peoples (Figure 1B).
Trends in MRSA in New Zealand, 2005–2011
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Molecular Epidemiology of MRSA Strains and Emergence
of ST5-IV Clone as the Dominant CA-MRSA Clone
Of the 3,323 isolates, 1569 (47.2%) were typed using phage
typing and 1754 (52.8%) typed using spa typing. Ten major MRSA
clonal complex (CC)/sequence types (ST) were identified over the
study period (Table 1). The seven most frequent MRSA clones
identified, accounting for 85.2% of all clinical MRSA, were ST30-
IV (24.8%), ST5-IV (20.4%), ST22-IV (18.8%), ST1-IV (10.2%),
ST8-IV (5.9%), ST93-IV (3.3%) and ST239-III (1.8%). Of the
3,323 MRSA isolates, 460 (13.9%) were unable to be assigned
a clonal complex or sequence type by phage typing (278 isolates)
or spa typing (182 isolates) (Table 1).
An ST5-IV MRSA clone was identified for the first time in the
2005 survey, and rapidly became the predominant CA-MRSA
clone in New Zealand. Representative isolates from this clone
were negative for the lukF-PV and lukS-PV genes. The relative
proportions of the seven predominant MRSA clones isolated from
clinical specimens between 2005–2011 are shown in Figure 2.
Notably, the proportion of ST5-IV increased significantly over the
study period, from 0.3% in 2005 to 34.7% in 2011 (P,0.001), and
the proportions of ST30-IV and ST22-IV decreased significantly
from 28.1 to 16.2% (P,0.001) and 37.8 to 8.9% (P,0.001),
respectively.
There was an age-related distribution of the seven commonest
MRSA clones, with ST22-IV isolated from older patients (median
age 79 years, interquartile range [IQR] 62–86 years), followed by
ST239-III (median 69 years, IQR 48–79 years), ST8-IV (median
37 years, IQR 18–61 years), ST30-IV (median 27 years, IQR 14–
43 years), ST1-IV (median 26 years, IQR 7–53 years) and ST5-IV
(median 17 years, IQR 4–42 years).
Isolation of other Emerging MRSA Strains in New Zealand
Fourteen patients with ST772-V MRSA (Bengal Bay MRSA)
were identified over the study period (2 patients in 2008; 4 in 2009;
2 in 2010 and 6 in 2011). Ten of these patients were of Indian
ethnicity. The spa types associated with ST772-V were t657 (10
isolates), t345 (one isolate) and t5310 (one isolate).
In addition, three patients with CA-MRSA isolates belonging to
CC398 were identified in 2011. The associated spa types were t034
(2 isolates) and t011.
Community vs. Healthcare-associated MRSA in New
Zealand
The period-prevalence rates of CA-MRSA and HCA-MRSA
infections are shown in Figure 3. The period-prevalence rate of
CA-MRSA increased significantly over the study period from 5.7
to 9.3 per 100,000 population (P,0.001). In addition, the period-
prevalence rate of HCA-CO MRSA increased from 2.4 to 7.4 per
100,000 population (P,0.001). In contrast, the period-prevalence
of HCA-HO MRSA did not change significantly over the study
period (Figure 3).
In comparison to patients with HCA-MRSA, patients with CA-
MRSA were significantly younger, more likely to be Māori or
Pacific Peoples, and were more likely to reside in a deprived
neighborhood (Table 2). In addition, there were distinct associa-
tions between specific MRSA clones and their isolation in either
the community or healthcare setting. ST30-IV, ST5-IV, and
ST93-IV were significantly more likely to be isolated from patients
in the community, whereas ST22-IV and ST239-III were more
likely to be isolated from patients in a healthcare setting (Table 2).
Discussion
To our knowledge, this represents the first study to systemat-
ically assess the clinical and molecular epidemiology of MRSA
from New Zealand. We analyzed seven years of data from our
national MRSA survey, and found that, although rates of MRSA
isolation were generally low in comparison to other developed
countries, there were notable demographic and epidemiological
findings.
Most notably, an ST5-IV clone rapidly emerged over the study
period and displaced ST30-IV as the dominant CA-MRSA clone.
Interestingly, unlike many other CA-MRSA clones, including
ST30-IV, this ST5-IV clone characteristically does not harbor the
lukF-PV and lukS-PV genes. MRSA strains belonging to ST5
represent a large and diverse group, and are geographically
widespread [26,27]. The origin of this recently emerged ST5-IV
strain in our region is unclear, but based on studies from other
settings it seems probable that this clone emerged from a locally
circulating ST5 methicillin-susceptible S. aureus (MSSA) strain
which acquired the small, mobile SCCmec-IV element [27]. Future
work should attempt to characterize the possible clinical and
Figure 1. Methicillin-resistant Staphylococcus aureus (MRSA) period-prevalence rates for clinical isolates in New Zealand, 2005–2011,
stratified by (A) age, and (B) ethnicity.
doi:10.1371/journal.pone.0062020.g001
Trends in MRSA in New Zealand, 2005–2011
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Table 1. Molecular epidemiology of methicillin-resistant Staphylococcus aureus isolates referred to the Institute of Environmental






Number analysed by spa
typing between 2009–2011 spa types (n)
ST30 (n=825) 484 341 t019 (309); t975(5); t1347(5); t138(4); t122(3); t1752(3); t021(2);
t779(2); t1133(1); t1273(1); t2895(1); t3723(1); t4341(1); t4672(1);
t5994(1); t6653(1)
ST5 (n =678) 148 530 t002(461); t045(23); t548(10); t062(7); t306(7); t010(4); t105(3);
t088(2); t1781(2); t5677(2); t009(1); t214(1); t242(1); t311(1);
t1154(1); t4323(1); t4865(1); t5213(1); t6787(1)
ST22 (n=625) 404 221 t032(153); t1401(14); t022(12); t1214(5); t852(4); t5501(4); t005(3);
t379(3); t5538(3); t718(2); t790(2); t5785(2); t7428(2); t557(1);
t578(1); t688(1); t749(1); t906(1); t1370(1); t1415(1); t1467(1);
t3612(1); t5836(1); t605(1); t6648(1)
ST1 (n =340) 129 211 t127(178); t701(11); t267(5); t386(3); t591(3); t7136(3); t359(1);
t521(1); t559(1); t693(1); t1418(1); t5100(1); t5736(1); t5837(1)
ST8 (n =196) 58 138 t008(118); t024(10); t2849(2); t6229(2); t711(1); t1610(1); t1627(1);
t1882(1); t2558(1); t4919(1)
ST93 (n=110) 10 100 t3949(66); t202(30); t1819(1); t4178(1); t6487(1); t7328(1)
ST239 (n=61) 47 14 t037(10); t631(1); t4150(2); t4866(1)
ST772 (n=14) 2 12 t657(10); t345 (1); t5310 (1)
ST36 (n=11) 9 2 t018(2)
CC398 (n =3) – 3 t034(2); t011(1)
Not determined (n =460) 278 182 t1853(24); t976(16); t375(14); t189(11); t437(9); t324(8); t282(6);
t148(4); t065(3), t179(3); t186(3); t216(3); t316(3); t1265(3);
t1767(3); t2143(3); t019(2); t021(2); t084(2); t121(2); t878(2);
t1781(2); t9257(2); t8493(2); t005(1); t026(1); t040(1); t044(1);
t064(1); t088(1); t089(1); t127(1); t237(1); t304(1); t442(1); t586(1);
t638(1); t688(1); t690(1); t771(1); t786(1); t791(1); t985(1); t1028(1);
t1126(1); t1309(1); t1839(1); t1849(1); t1895(1); t2062(1); t2078(1);
t2085(1); t2321(1); t2815(1); t3979(1); t4359(1); t4448(1); t4467(1);
t5110(1); t5181(1); t5190(1); t5191(1); t5562(1); t5782(1); t5784(1);
t6256(1); t6681(1); t7211(1); t7334(1); t8349(1); t9258(1); t9269(1);
t9508(1)
Total (n =3323) 1569 1754 –
doi:10.1371/journal.pone.0062020.t001
Figure 2. Relative proportions of methicillin-resistant Staphylococcus aureus (MRSA) clones circulating in New Zealand, 2005–2011.
doi:10.1371/journal.pone.0062020.g002
Trends in MRSA in New Zealand, 2005–2011
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molecular reasons for the successful emergence of this clone in
New Zealand.
In addition, we observed a significant increase in the burden of
CA-MRSA disease over the study period. In our setting, this was
largely due to two CA-MRSA clones, ST30-IV and ST5-IV. The
reasons for the marked increase in CA-MRSA over the study
period are unclear, but may, in part, reflect the increasing
incidence of SSTI in New Zealand over the past decade [28,29].
Of note, the population groups with the highest burden of SSTI in
New Zealand, namely Māori and Pacific Peoples, are the same
population groups that carry the greatest burden of CA-MRSA
disease. A strong association between CA-MRSA disease and
distinct indigenous groups in other settings has been previously
described, including Aboriginal Australians [30], and American
Indians [1]. The reasons for this association are multifactorial, but
are likely to involve a combination of poor hygiene, nutrition and
domestic crowding [28–30]. Further research should attempt to
understand the interaction of host and sociodemographic factors
that predispose to CA-MRSA infection in these groups.
We also observed a three-fold increase in the burden of
community-associated MRSA disease in patients with prior
healthcare exposure (HCA-CO MRSA). The reasons for this
significant increase are uncertain, but it seems probable that
a number of factors may have contributed, including an increase
in the community reservoir of MRSA and changes in the delivery
of healthcare, such that many medical treatments and procedures
are now undertaken in a community setting. As such, the clinical
and molecular epidemiology of HCA-CO MRSA disease may
share both community and hospital characteristics. In our data,
this was reflected by the specific MRSA clones causing HCA-CO
disease; it was notable that ST5-IV and ST30-IV, both clones
which are predominantly associated with CA-MRSA, contributed
to approximately 40% of HCA-CO MRSA isolates. The in-
filtration of CA-MRSA clones into the healthcare setting has been
recently described, and it has been suggested that CA-MRSA
strains may ultimately replace traditional HCA-MRSA strains in
the healthcare environment [9]. However, despite the increase in
HCA-CO MRSA, we did not observe any increase in HCA-HO
MRSA over the study period. This may, in part, be due to local
initiatives over the past several years designed to prevent
healthcare-associated infections, in particular a national campaign
to improve hand hygiene compliance in acute care settings [31].
Future efforts should be directed towards reducing the rate of
HCA-HO MRSA even further, in addition to addressing the
increasing burden of HCA-CO MRSA.
Interestingly, we also observed the emergence of several clones
associated with CA-MRSA disease in other geographic settings,
most notably the ST8-IV USA300 clone from North America and
the ST93-IV Queensland clone from Australia. Although we did
not have specific epidemiological information relating to overseas
travel, it seems probable that emergence of these clones in New
Zealand was due to sporadic introduction and ‘‘spillover’’ from
other settings with ensuing community spread, rather than local
emergence of these clones. Of concern was the observation that
the USA300 clone accounted for approximately 6% of HCA-HO
MRSA isolations over the study period. This successful clone is
notable for its apparent transmissibility and ability to harbor
several virulence factors [1]. Of further concern was our finding of
fourteen MRSA isolates belonging to ST772-V. ST772-V MRSA,
also dubbed the ‘‘Bengal Bay clone’’, is noted for its resistance to
multiple antibiotic classes and its ability to harbor several virulence
factors including the lukF-PV and lukS-PV genes and the
enterotoxin gene cluster (egc) [32]. An epidemiological link with
travel to the Indian subcontinent has previously been described for
patients from whom ST772 MRSA has been isolated [32].
Although we did not have information related to overseas travel, it
is notable that of the fourteen patients with ST772 MRSA in New
Zealand, ten (71%) were of Indian ethnicity.
There were a number of limitations with our study. Most
notably, we did not have information relating to clinical
syndromes associated with specific MRSA clones. Future pro-
spective studies should monitor the type and severity of disease
caused by MRSA in our setting, particularly in light of the recent
emergence of the lukF-PV/lukS-PV-negative ST5-IV clone. In
Figure 3. Period-prevalence rates of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), healthcare-
associated community-onset MRSA (HCA-CO MRSA) and healthcare-associated hospital-onset (HCA-HO MRSA) in New Zealand,
2005–2011.
doi:10.1371/journal.pone.0062020.g003
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addition, the data we analyzed was based on annual monthly
‘‘snapshot’’ surveys, rather than continuous surveillance. As such,
we had no information on MRSA colonisation/infection from the
time periods outside the annual surveys. Despite this limitation
however, isolates and data were collected consistently each year,
and from all diagnostic microbiology laboratories in New Zealand,
thus providing a nationally representative profile of the epidemi-
ology of MRSA. Finally, in this study, we focused exclusively on
MRSA. In our setting however, S. aureus disease is predominantly
due to MSSA strains, which frequently harbor the lukF-PV/lukS-
PV genes [25]. Future studies should attempt to assess the clinical
and molecular epidemiology of disease caused not only by MRSA,
but also by MSSA.
In summary, we found notable temporal and sociodemographic
differences in the epidemiology of MRSA in New Zealand. The
increase in CA-MRSA was consistent with reports from other
settings, and the burden of CA-MRSA was disproportionately
carried by the Māori and Pacific Peoples ethnic groups. We
identified several MRSA clones not previously known to circulate
in New Zealand, including an ST5-IV clone that rapidly displaced
ST30-IV as the dominant CA-MRSA clone. Of particular concern
was the finding of several successful and virulent MRSA clones
from other geographic settings, including ST93-IV (Queensland
CA-MRSA), ST8-IV (USA300) and ST772-V (Bengal Bay
MRSA). Ongoing molecular surveillance is essential to ensure
early identification and tracking of such strains, and to prevent
these MRSA strains becoming endemic in the New Zealand
healthcare setting.
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